ALK and non-small cell lung carcinoma: This can be explained by the availability of two additional ALK inhibitors for the treatment of ALK-positive non-small cell lung cancer (NSCLC) through the drug alectinib, launched in Germany in 2017, and the drug lorlatinib, launched in 2019.